Our Trials


Men who choose radical surgery for prostate cancer (radical prostatectomy) can experience side effects, including urine leakage and problems with erections.
This project aims to develop a new questionnaire for measuring urinary and sexual function following radical prostatectomy in men in the UK.

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men1. Men presenting with metastatic disease have a median survival of only 42.1 months2 and current standard-of-care consists of initial androgen deprivation therapy (ADT) followed by chemotherapy and novel agents once the cancer no longer responds to ADT. The burden on the health care setting of treating men with metastatic prostate cancer is vast and a recent study estimated costs of USD20,000 per man3. There is emerging data that radical therapy directed at the prostate impacts survival, especially in those with limited metastatic burden, defined as 1-3 skeletal lesions without any visceral metastases (oligo-metastases). Further, many men suffer symptomatic disease progression and eventually require palliative surgical intervention, which is less frequent in those treated with initial radical prostatectomy compared to systemic therapy alone4,5. Hence, our ultimate aim is to examine whether radical prostatectomy can impact survival and quality-of-life in men with oligo-metastatic prostate cancer. Currently we have low-level evidence from biological and epidemiological studies and we need to provide a high level of evidence with a clinical trial to properly interrogate the hypothesis that radical prostatectomy improves survival in men with oligo-metastatic prostate cancer. However, randomisation to surgical trials is fraught with difficulty and a number of high-profile prostate cancer trials have failed to recruit. Hence, before commencing a full trial, it is imperative to assess the feasibility of the study. One major success in recruitment terms was the Prostate Testing for Cancer and Treatment (ProtecT) study (http://www.nets.nihr.ac.uk/projects/hta/962099) which employed a qualitative recruitment investigation (QRI) run by the University of Bristol School of Social and Community Medicine; we will therefore similarly integrate a QRI in this feasibility study.
An Open label phase I / randomized, double blind phase II study in metastatic castration resistant Prostate Cancer of AZD5363 in combination with Docetaxel and Prednisolone chemotherapy (DP)


This study is for patients with metastatic castration resistant prostate cancer who are suitable to receive palliative docetaxel chemotherapy.


The overall aim of this study is to determine if the addition of the AKT inhibitor AZD5363 to docetaxel and prednisolone prolongs progression free survival to a degree worthy of further investigation

This is a multi-centre, randomised controlled trial for patients with locally advanced or metastatic prostate cancer who are about to commence androgen suppression (AS) therapy. The trial aims to investigate the efficacy and safety of 3 different drugs in combination with AS. The drugs are zoledronic acid, docletaxel and celecoxib.

All patients will receive AS, men in the research arms will receive one or two of the research drugs as well.

Prostate cancer  is one of the commonest cancer in men in the Western world, with over 40,000 new cases diagnosed each year in the United Kingdom (UK). Research studies have identified several genetic changes that are thought to increase the risk of developing prostate cancer. Some of these genetic changes occur in DNA repair genes. The BARCODE 2 study is formed of two parts that aim to investigate how having genetic changes in DNA repair genes can affect response to treatment. In part 1 of the study, the investigators will invite men with metastatic castration resistant prostate cancer (mCRPC) who have not had genetic testing before to join the study by initially undergoing genetic screening within the study. If a pathogenic mutation is confirmed in one of these genes, patients will be given the option to proceed to part 2 of the study. In part 2 of the study, men with mCRPC who are known to be carriers of a mutation in DNA repair gene(s) will be assessed for eligibility for treatment on the study. The aim of the study will be to determine how patients with mCRPC and a germline mutation in a DNA repair gene(s) respond to platinum chemotherapy. This study will help researchers to investigate the platinum sensitivity of prostate tumours that have developed due to a germline mutation in a DNA repair gene. This study will provide data to use in a larger clinical trial of platinum chemotherapy based on patients’ germline genetic signature and/or tumour genetic profile.

©2019 Royal Surrey County Hospital

Log in with your credentials

Forgot your details?